Evidence map›Paper›PMID 36711008›Full record

ArticleBlood cell therapy2020

Salvage Transplantation with Cord Blood for Graft Rejection of Peripheral Blood Stem Cells due to Donor Specific Antibody.

Maria Regina Pelobello de Leon, Shuichiro Takahashi, Masahiro Onozawa, Makoto Ito, Manabu Nakano, Hajime Senjo, Masahiro Chiba, Hiroyuki Ohigashi, Emi Yokoyama, Junichi Sugita and 2 more

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cell therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Maria Regina Pelobello de LeonDepartment of Hematology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Shuichiro TakahashiDepartment of Hematology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Masahiro OnozawaDepartment of Hematology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Makoto ItoDivision of Laboratory and Transfusion Medicine, Hokkaido University Hospital, Sapporo, Japan.
Manabu NakanoJapanese Red Cross Hokkaido Block Blood Center, Sapporo, Japan.
Hajime SenjoDepartment of Hematology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Masahiro ChibaDepartment of Hematology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Hiroyuki OhigashiDepartment of Hematology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Emi YokoyamaDepartment of Hematology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Junichi SugitaDepartment of Hematology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Daigo HashimotoDepartment of Hematology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Takanori TeshimaDepartment of Hematology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Hokkaido University · JPHokkaido University Hospital · JPJapanese Red Cross Society, Japan · JPSapporo Hokuyu Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative therapy for various kinds of hematological malignancies and disorders. Recently, HLA-haploidentical stem cell transplantation with post-transplantation cyclophosphamide (PTCy-haplo HSCT) has been widely performed due to its safety and favorable immune recovery. However, graft rejection remains an obstacle to PTCy-haplo HSCT. Donor specific antibody (DSA) is considered to be a major factor of graft rejection of haplo HSCT. We herein present a case of graft rejection after PTCy haplo-HSCT due to DSA induced by pretransplant platelet transfusion after donor selection. The patient was dependent on platelet transfusion and had not received cytotoxic chemotherapy because he was diagnosed as myelodysplastic syndrome/myeloproliferative neoplasm-unclassifiable. We retrospectively confirmed the level of DSA just before the first transplantation and found that it was dramatically elevated, which was enough to cause graft rejection. We successfully performed cord blood transplantation of the HLA that was not the target of DSA, as salvage transplantation without any desensitization. This case illustrates that we have to confirm the presence of DSA immediately before the haplo-HSCT, particularly in high risk patients who are dependent on platelet transfusion and have no cytotoxic chemotherapy before HSCT.

Indexed as

cord blood transplantationdonor specific antibodygraft rejectionhaploidentical transplantationposttransplantation cyclophosphamide

Identifiers

PMID36711008
PMCPMC9847262
OpenAlexW4237447779

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.